FundedIQ
Biotechnology

Curevo: Funding, Investors & Team (Nov 2026)

In order to expedite the creation of safe and highly efficient vaccines from the bench through clinical testing, Curevo will integrate the best aspects of protein science and adjuvant technology. Curevo will concentrate on diseases that can be prevented by vaccination that are widespread in both the Asian and US markets but for which there are currently no vaccine products available. By collaborating with the Seattle, Washington-based Infectious Disease Research Institute, the South Korean Mogam Institute for Biomedical Research, and GC Pharma, Cuervo hopes to quickly advance novel new vaccine candidates from the research lab to the clinic.

www.curevovaccine.com LinkedIn Bothell, United States 11-50 employees
Biopharma Biotechnology Health CareVaccines Adjuvants Public health Infectious disease Drug discovery Drug development
Total raised
$26.0M
Rounds
1
Latest
Series A
Nov 2022

Curevo has raised $26.0M across 1 funding round on record, the most recent a Series A of $26.0M announced in Nov 2022.

That round is above the $8.9M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Curevo Company Profile and Key Stats

Total funding raised
$26.0M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series A
$26.0M in Nov 2022
Employees
11-50
reported band
Headquarters
Bothell, United States

Latest funding round on record: Nov 2022.

Curevo Funding Rounds

Date
Round
Amount
Series A
$26.0M

Curevo Founders and Leadership Team

Name
Role
Contact
George Simeon
CEO
Locked

Contact details for the Curevo team: 1 of 1 has an email address on file.

Start 14-day free trial →

Curevo Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,188
$8.9M
30,615
$7.8M
8,738
$15M

Curevo's latest round of $26.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Curevo in Biotechnology and Bothell

Companies Similar to Curevo

Araceli Biosciences specializes in creating scientific instruments for discovering tissue- and cell-based…

Seed $4.5M

Switchpoint Bio is a biotechnology company that offers immune relevant drug treatments.

Pre-Seed $5.3M

Nanopath Inc. is a company that specializes in molecular diagnostics and allows for fast, high-quality…

Series B $25.0M

Frontier Bio is creating lab-grown human tissues as an ethical replacement for animal studies and is setting…

Undisclosed round $380k

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel…

Series C $100M

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…

Series B $41.9M

Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…

Series A $6.0M

Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…

Series D —

Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…

Undisclosed round $21.5M

100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…

Pre-Seed $110k

MEND is a company focused on life sciences, determined to assist individuals in achieving better health…

Undisclosed round $1.5M

Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…

Series B $50.0M

Curevo Funding FAQs

What does Curevo do?

In order to expedite the creation of safe and highly efficient vaccines from the bench through clinical testing, Curevo will integrate the best aspects of protein science and adjuvant technology. Curevo will concentrate on diseases that can be prevented by vaccination that are widespread in both the Asian and US markets but for which there are currently no vaccine products available. By collaborating with the Seattle, Washington-based Infectious Disease Research Institute, the South Korean Mogam Institute for Biomedical Research, and GC Pharma, Cuervo hopes to quickly advance novel new vaccine candidates from the research lab to the clinic.

How much funding has Curevo raised?

Curevo has raised $26.0M across 1 round on record. The most recent is a Series A of $26.0M announced in Nov 2022.

When did Curevo last raise funding?

Curevo's most recent funding round on record is a Series A of $26.0M, announced in Nov 2022.

Who is the CEO of Curevo?

George Simeon is listed as CEO at Curevo.

Where is Curevo headquartered?

Curevo is based in Bothell, Washington, United States.

How many employees does Curevo have?

Curevo is in the 11-50 employee band.

How does Curevo's funding compare to other Biotechnology startups?

Curevo's latest round of $26.0M is above the $8.9M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.

About FundedIQ's Curevo Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Curevo is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.

Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.